Abstract
Glutamatergic neurotransmission modulators have been already used in the treatment of Alzheimer`s disease and some affective disorders. Dysfunction of glutamatergic neurotransmission may be also involved in pathophysilogy of schizophrenia.
There is evidence of positive therapeutic effects of agonists of glycine modulatory site of NMDA receptors on symptoms of schizophrenia in clinical trials. The drugs modulating extracellular levels of NMDA receptor agonists and AMPA receptor modulators are currently under clinical evaluation.
The hypothesis of glutamatergic hyperfunction proposed the effect of glutamate release-inibiting drugs in schizophrenia. Posisive therapeutic effect of lamotrigine in add-on therapy has been demostrated in patients with schizophrenia treated with atypical antipsychotics.